Skip to main content

Table 3 Meta-analysis of MSCs versus traditional regimens as induction therapy

From: Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis

Outcomes Number of trials Number of patients RR/WMD 95% CI p value Heterogeneity p value (%)
1-year AR rate 4 197 0.77 0.41,1.45 0.42 18
1-year graft survival rate 3 160 0.99 0.93,1.05 0.69 0
1-year infection rate 4 197 0.65 0.46,0.9 0.01 3
DGF rate 2 145 0.54 0.21,1.38 0.2 34
Renal graft function postsurgery
 1 month 3 155 -1.56 −14.2, 11.08 0.81 72
 3 month 3 155 0.15 −5.63,5.93 0.96 0
 6 month 3 155 −1.95 −9.87,5.97 0.63 62
 12 month 4 197 −1.13 −7.16,4.89 0.71 0
  1. MSCs mesenchymal stromal cells, AR acute rejection, DGF delay graft function, RR risk ratio, WMD weighted mean difference, CI confidence intervals